MX2019002437A - Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon. - Google Patents

Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon.

Info

Publication number
MX2019002437A
MX2019002437A MX2019002437A MX2019002437A MX2019002437A MX 2019002437 A MX2019002437 A MX 2019002437A MX 2019002437 A MX2019002437 A MX 2019002437A MX 2019002437 A MX2019002437 A MX 2019002437A MX 2019002437 A MX2019002437 A MX 2019002437A
Authority
MX
Mexico
Prior art keywords
insulin resistance
signaling pathway
severe insulin
methods
inhibitor
Prior art date
Application number
MX2019002437A
Other languages
English (en)
Inventor
Okamoto Haruka
Gromada Jesper
JASPERS Stephen
Harp Joyce
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019002437A publication Critical patent/MX2019002437A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

En este documento se proporcionan métodos para tratar a un paciente con resistencia severa a la insulina. Los métodos comprenden administrar a un paciente que lo necesite una cantidad terapéutica de un inhibidor de la vía de señalización de GCG/GCGR, de manera que los niveles de glucosa en sangre o beta-hidroxibutirato disminuyan o que la resistencia severa a la insulina esté mediada, o una afección o enfermedad caracterizada por resistencia severa a la insulina es mediada, o al menos un síntoma o complicación asociada con la afección o enfermedad se alivia o reduce su gravedad. El inhibidor de la vía de señalización de GCG/GCGR puede ser un inhibidor de molécula pequeña de la vía de señalización, un inhibidor antisentido de la vía de señalización, un anticuerpo monoclonal neutralizante de GCG, un antagonista de GCGR, un péptido inhibidor de la vía de señalización, un DARPin, un Spiegelmer, un aptámero, dominios Fn de tipo III diseñados por ingeniería genética, etc. Los métodos terapéuticos son útiles para tratar a un ser humano que padece de resistencia severa a la insulina.
MX2019002437A 2016-08-30 2017-08-29 Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon. MX2019002437A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662381263P 2016-08-30 2016-08-30
US201662411032P 2016-10-21 2016-10-21
PCT/US2017/049137 WO2018044903A1 (en) 2016-08-30 2017-08-29 Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

Publications (1)

Publication Number Publication Date
MX2019002437A true MX2019002437A (es) 2019-10-09

Family

ID=59799505

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002437A MX2019002437A (es) 2016-08-30 2017-08-29 Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon.
MX2021006457A MX2021006457A (es) 2016-08-30 2019-02-28 Anticuerpo inhibidor para usarse para tratar la resistencia severa a la insulina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006457A MX2021006457A (es) 2016-08-30 2019-02-28 Anticuerpo inhibidor para usarse para tratar la resistencia severa a la insulina.

Country Status (11)

Country Link
US (3) US10995146B2 (es)
EP (1) EP3506940A1 (es)
JP (2) JP7173962B2 (es)
KR (2) KR20230062673A (es)
CN (1) CN109922831A (es)
AU (1) AU2017321423A1 (es)
CA (1) CA3034777A1 (es)
MA (1) MA46089A (es)
MX (2) MX2019002437A (es)
SG (2) SG11201901355SA (es)
WO (1) WO2018044903A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901355SA (en) 2016-08-30 2019-03-28 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN113481290B (zh) * 2021-06-30 2022-08-23 华南农业大学 一种klf4基因在制备检测和/或减少母鼠不良妊娠结局的产品中的应用
CN114342875A (zh) * 2022-01-12 2022-04-15 吉林大学 一种新型妊娠糖尿病动物模型的建立方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836308B2 (ja) 1977-02-10 1983-08-08 大塚製薬株式会社 抗体の製造方法
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
JPS56163456A (en) 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
RU2184779C2 (ru) 1992-08-28 2002-07-10 Ново Нордиск А/С Изолированная молекула днк, кодирующая рецептор глюкагона, днк-конструкция, линия клеток, способ получения рецептора глюкагона, изолированный пептид рецептора глюкагона, изолированное антитело, зонд, способ обнаружения присутствия антагонистов глюкагона
JP2729159B2 (ja) 1994-10-31 1998-03-18 日清製粉株式会社 ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
AU2004312001B2 (en) 2003-12-19 2009-08-27 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
MY143599A (en) 2004-06-04 2011-06-15 Merck Sharp & Dohme Pyrazole derivatives, compositions containing such compounds and methods of use
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
ATE449604T1 (de) 2004-07-07 2009-12-15 Merck & Co Inc Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
EP1773330B1 (en) 2004-07-22 2010-05-26 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US8084489B2 (en) 2005-02-11 2011-12-27 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
JP2008533200A (ja) 2005-03-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド 置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CA2649751A1 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compound/glucagon antibody compositions
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
PE20091674A1 (es) 2008-03-27 2009-11-04 Lilly Co Eli Antagonistas del receptor de glucagon
JP2011520897A (ja) 2008-05-16 2011-07-21 シェーリング コーポレイション グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法
WO2010030722A1 (en) 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8445538B2 (en) 2008-12-19 2013-05-21 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
US20110281795A1 (en) 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098948A1 (en) 2009-02-13 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012188352A (ja) 2009-07-13 2012-10-04 Dainippon Sumitomo Pharma Co Ltd ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP3401401B1 (en) 2011-09-20 2020-04-15 Ionis Pharmaceuticals, Inc. Antisense modulation of gcgr expression
WO2013081993A1 (en) 2011-12-02 2013-06-06 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
AU2014264295A1 (en) 2013-05-07 2015-10-29 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
JP2017533695A (ja) * 2014-09-16 2017-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗グルカゴン抗体およびその使用
SG11201901355SA (en) 2016-08-30 2019-03-28 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

Also Published As

Publication number Publication date
KR20230062673A (ko) 2023-05-09
CA3034777A1 (en) 2018-03-08
JP7173962B2 (ja) 2022-11-16
CN109922831A (zh) 2019-06-21
RU2019107807A (ru) 2020-10-01
US20210221896A1 (en) 2021-07-22
JP2022140605A (ja) 2022-09-26
MX2021006457A (es) 2021-07-02
US10995146B2 (en) 2021-05-04
SG11201901355SA (en) 2019-03-28
WO2018044903A1 (en) 2018-03-08
US20230416384A1 (en) 2023-12-28
EP3506940A1 (en) 2019-07-10
RU2019107807A3 (es) 2021-05-18
JP2019528306A (ja) 2019-10-10
AU2017321423A1 (en) 2019-03-14
MA46089A (fr) 2019-07-10
US11708416B2 (en) 2023-07-25
US20190218301A1 (en) 2019-07-18
KR20190044079A (ko) 2019-04-29
SG10201913074WA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
MX2021006457A (es) Anticuerpo inhibidor para usarse para tratar la resistencia severa a la insulina.
EA201690606A1 (ru) Аналоги глюкагона
MX2022009625A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
IN2012DN02521A (es)
MX2011012691A (es) Combinacion de un antagonista de tnf-alfa y un antagonista de vegf para utilizarse en el tratamiento o en la prevencion de enfermedades de los ojos.
PH12019501026A1 (en) Myostatin, activin or activin receptor antagonists for use in treating obesity and related conditions
EA201590294A1 (ru) Аналоги глюкагона
UY37049A (es) Método para tratar o aliviar trastornos metabólicos usando proteínas de unión para el receptor peptídico inhibidor 25 gástrico (gipr) en combinación con agonistas del glp-1
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
BR112016022754A2 (pt) derivados de exendina-4 como agonistas peptídicos duplos dos receptores de glp-1 / glucagon
EA201690494A1 (ru) Ацилированные аналоги глюкагона
EA201500364A1 (ru) Лечение глазных заболеваний
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
BR112017027549A2 (pt) anticorpo para cd40
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MX2018004531A (es) Proteinas de union a antigeno que activan el receptor de leptina.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
PH12015502547A1 (en) Anti-glucagon receptor antibodies and methods of use thereof
NZ739392A (en) Methods for treating hepcidin-mediated disorders
MX2020006508A (es) Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas.
AR082312A1 (es) Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos
MX2020002057A (es) Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon.